According to the publication, the company is expanding the production of its vaccine outside the United States.
The American company Moderna is building two new production lines, the launch of which will allow it to increase the production of coronavirus vaccines by 50%, currently carried out at the company’s facility in Norwood, a suburb of Boston (Massachusetts). This was reported by The Wall Street Journal on Monday, citing a statement by the head of Moderna, Stephane Bancel.
The head of the company noted that the increase in production of the drug will not only meet the needs for it in the United States itself but also make it possible in the future to export this vaccine to other countries.
“We plan and hope that as soon as the United States has sufficient [stocks] of the vaccine, we will be allowed to export it so that we can help as many countries around the world as possible,” the publication quotes Bancel as saying.
The first of the production lines under construction is planned to be launched in the coming autumn, the second – in early 2022. The company, the newspaper writes, is also expanding production of its vaccine outside the United States, which – with the assistance of its partners-will allow it to bring the production of the drug to about 3 billion doses in 2022, compared to 1 billion doses planned for production this year.